FY2024 EPS Estimate for Keros Therapeutics Cut by Analyst

Keros Therapeutics, Inc. (NASDAQ:KROS) – Analysts at Leerink Partnrs lowered their FY2024 EPS estimates for shares of Keros Therapeutics in a research report issued to clients and investors on Thursday, November 7th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings of ($5.26) per share for the year, down from their prior estimate of ($4.76). The consensus estimate for Keros Therapeutics’ current full-year earnings is ($5.14) per share. Leerink Partnrs also issued estimates for Keros Therapeutics’ Q4 2024 earnings at ($1.36) EPS, FY2025 earnings at ($5.84) EPS, FY2026 earnings at ($6.58) EPS, FY2027 earnings at ($3.79) EPS and FY2028 earnings at $1.48 EPS.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm had revenue of $0.39 million for the quarter. During the same quarter in the previous year, the company earned ($1.33) earnings per share. Keros Therapeutics’s revenue was up 4750.0% on a year-over-year basis.

A number of other analysts have also recently commented on the stock. Scotiabank assumed coverage on shares of Keros Therapeutics in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a research report on Thursday, November 7th. Guggenheim started coverage on Keros Therapeutics in a research report on Monday, September 23rd. They issued a “buy” rating and a $96.00 price target for the company. Cantor Fitzgerald assumed coverage on Keros Therapeutics in a report on Thursday, October 24th. They set an “overweight” rating on the stock. Finally, Jefferies Financial Group assumed coverage on Keros Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating for the company. Twelve investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Keros Therapeutics has a consensus rating of “Buy” and an average price target of $88.89.

Keros Therapeutics Stock Up 0.4 %

NASDAQ KROS opened at $68.15 on Monday. The company has a market cap of $2.56 billion, a PE ratio of -13.08 and a beta of 1.23. Keros Therapeutics has a 52 week low of $27.31 and a 52 week high of $73.00. The firm’s 50-day simple moving average is $58.65 and its two-hundred day simple moving average is $52.23.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. KBC Group NV lifted its position in Keros Therapeutics by 52.0% during the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after purchasing an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after buying an additional 280 shares in the last quarter. Values First Advisors Inc. bought a new stake in shares of Keros Therapeutics during the 3rd quarter worth $89,000. Ameritas Investment Partners Inc. grew its position in Keros Therapeutics by 14.5% in the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock worth $169,000 after acquiring an additional 324 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Keros Therapeutics in the second quarter worth $128,000. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.